Great Lakes Pharmaceuticals, Inc. is a clinical stage company focused on developing and commercializing products that prevent infections associated with indwelling catheters.
The company's first product, B-Lock™, is an anti-coagulant catheter lock solution that works against the bacterial and fungal microorganisms known to form biofilm structures in catheters. Biofilm related infections are the eighth leading cause of death in the U.S., and currently, there are no antibiofilm products on the market for treatment and prevention, in particular in the prevention of intra-luminal infections.
Great Lakes Pharmaceuticals is preparing testing of its first antibiofilm products effective in prevention of catheter-associated infections in clinical studies in the U.S. and select EU countries.
Initial JumpStart Investment: December 2006
For more information on Great Lakes Pharmaceuticals, contact: Jerry Frantz